ArticleIndian journal of psychiatry2025
Translational significance of neurodevelopment underpinned 'neurophysiological-cognitive' biomarkers in schizophrenia.
Article in Indian journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarker research helps validate diagnostic entities that are otherwise based on pure clinical sense and prone to subjectivity bias. Biomarker research in the field of schizophrenia and psychoses dates back to more than a century. However, the focus on 'translational' biomarkers in schizophrenia is a more recent one, dating to the turn of the last century. The translational biomarker research in schizophrenia encompasses diagnostic markers, endophenotypes, and theranostic markers. A prime objective of translational biomarkers in schizophrenia is to enhance the field of identification of high-risk states and prevent the onset of illness. The two-hit theory within the neurodevelopmental hypothesis that also takes into account the role of neuroinflammation has by far been the major contributor to the genesis of several translational biomarkers in schizophrenia. Several neurophysiological biomarkers have been identified based on the two-hit theory. Also, identification of electrophysiological biomarkers, specifically electroencephalographic (EEG), both resting state and task-driven, is more feasible in low-cost settings. Furthermore, proof-of-concept trials including the combined use of biomarkers and novel treatment strategies and the use of bioinformatics and computational intelligence for improving theranostics fall under the broad rubric of translational biomarker research in schizophrenia. This oration is a narrative review of various translational biomarkers in schizophrenia with a focus on neurodevelopmentally based cognitive-electrophysiological measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.